Search
Praxis Precision Medicines Inc
PRAXAdd to Watchlist
307.830USD
+0.080+0.03%
Close 07-31 16:00（ET）Quotes delayed by 15 min
8.58BMarket Cap
LossP/E TTM
Earnings Forecast
Currency: USD Updated: 2026-07-31The current earnings forecast score of Praxis Precision Medicines Inc is 8.32, ranking 140 out of 385 in the Biotechnology & Medical Research industry. The average price target is 340.00, with a high of 760.00 and a low of 65.00.
Analyst Rating
Based on
19
analysts
Buy
Current Rating
603.895
Target Price
+107.50%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
496
Total
6
Median
7
Average
Company name
Ratings
Analysts
Praxis Precision Medicines Inc
PRAX
19
Beigene Ltd
ONC
28
argenx SE
ARGX
26
Ionis Pharmaceuticals Inc
IONS
26
IQVIA Holdings Inc
IQV
25
Insmed Inc
INSM
23
1
2
3
...
99
Support & Resistance
Relevant data have not been disclosed by the company yet.
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
FAQs
What is Praxis Precision Medicines Inc's price target?
Analysts forecast that Praxis Precision Medicines Inc's price target is USD 340.00, with the highest forecast at USD 760.00 and the lowest forecast at USD 65.00.
How have Praxis Precision Medicines IncPRAX's recent earnings per share performed?
The market expectation was USD -3.20, while Praxis Precision Medicines IncPRAX's earnings per share (EPS) for the previous quarter was USD -3.49. EPS for the next quarter is expected at USD -3.66.
What is the analyst rating for Praxis Precision Medicines Inc?
Based on the ratings of Praxis Precision Medicines Inc's stock from 19 analysts, most analysts support a Buy trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Buy. Please note that this is not trading advice. You still need to conduct your own analysis.